Last reviewed · How we verify
CBT101 cells, every 2 weeks — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CBT101 cells, every 2 weeks (CBT101 cells, every 2 weeks) — CHABiotech CO., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CBT101 cells, every 2 weeks TARGET | CBT101 cells, every 2 weeks | CHABiotech CO., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CBT101 cells, every 2 weeks CI watch — RSS
- CBT101 cells, every 2 weeks CI watch — Atom
- CBT101 cells, every 2 weeks CI watch — JSON
- CBT101 cells, every 2 weeks alone — RSS
Cite this brief
Drug Landscape (2026). CBT101 cells, every 2 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/cbt101-cells-every-2-weeks. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing